Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

, NVO

Novo Nordisk

$49.46

0.805 (1.65%)

15:44
07/10/18
07/10
15:44
07/10/18
15:44

Roche, Gilead, Novartis nix some drug price increases, Bloomberg says

Gilead (GILD), Roche (RHHBY), Novo Nordisk (NVO) and Novartis (NVS) have all sent notices to California health plans rescinding or reducing previously announced price hikes in the wake of a new drug pricing transparency law that was enacted in the state, according to Bloomberg. The California measure, which is among the most aggressive efforts by states to rein in drug costs, is being challenged in court by the drug industry's lobbying group, the report noted. The walk back on the price hikes also follows President Donald Trump's recent promise that a number of drug companies will be voluntarily lowering their prices. Other large cap pharmaceutical companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Pfizer (PFE), and Sanofi (SNY). Reference Link

RHHBY

Roche

$0.00

(0.00%)

NVO

Novo Nordisk

$49.46

0.805 (1.65%)

NVS

Novartis

$77.34

-0.12 (-0.15%)

AZN

AstraZeneca

$35.61

0.26 (0.74%)

BMY

Bristol-Myers

$56.26

-0.19 (-0.34%)

LLY

Eli Lilly

$88.14

0.26 (0.30%)

GSK

GlaxoSmithKline

$41.43

0.42 (1.02%)

JNJ

Johnson & Johnson

$127.29

1.18 (0.94%)

MRK

Merck

$62.41

0.38 (0.61%)

PFE

Pfizer

$37.50

0.325 (0.87%)

SNY

Sanofi

$42.13

0.29 (0.69%)

  • 10

    Jul

  • 10

    Jul

  • 10

    Jul

  • 12

    Jul

  • 17

    Jul

  • 24

    Jul

  • 25

    Jul

  • 27

    Jul

  • 22

    Aug

  • 10

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

RHHBY Roche
$0.00

(0.00%)

06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/21/18
RHCO
06/21/18
NO CHANGE
Target $150
RHCO
Buy
Tesaro takeout range is around $153 per share, says SunTrust
SunTrust analyst Peter Dawson notes yesterday's speculation in Intereconomia.com about a potential acquisition of Tesaro (TSRO) by Roche (RHHBY), saying his M&A valuation analysis puts a potential takeout value on Tesare at $153 per share or about $8.4B. The analyst says the rumor is also positive for other PARP inhibitor players like Clovis (CLVS) as well as Tesaro's oncology peers. Dawson keeps his Buy rating and $150 price target on Tesaro stock.
06/20/18
RBCM
06/20/18
NO CHANGE
RBCM
Sector Perform
RBC Capital 'skeptical' on 'unsubstantiated' reports Roche eyeing Tesaro buyout
RBC Capital analyst Kennen Mackay said he is "skeptical" of "unsubstantiated" media reports suggesting Roche (RHHBY) is interested in buying Tesaro (TSRO) given what he sees as lack of a compelling strategic rationale for such a deal. Given Zejula's trajectory to date and increasing competition in the recurrent maintenance ovarian cancer market, Mackay continues to expect Street estimates to be lowered for Tesaro. He also thinks Roche is focused on developing or acquiring "best-in-class" molecules, and given this context Mackay sees Rubraca as a potentially better fit than Zejula, he tells investors. Mackay keeps a Sector Perform rating and $46 price target on Tesaro shares.
06/20/18
SBSH
06/20/18
NO CHANGE
Target $100
SBSH
Buy
Tesaro could be valued at $140-$213 in takeover scenario, says Citi
Citi analyst Robyn Karnauskas said that investors have been asking about her M&A analysis for Tesaro, which she has published previously. Her analysis suggests the company could be valued at $140-$213 per share in a takeover scenario, noted Karnauskas, who maintains a Buy rating and $100 price target on Tesaro shares. The questions may have increased after Spanish website Intereconomia reported that following its acquisition of Foundation Medicine (FMI), Roche (RHHBY) is working with Citibank on a potential acquisition of Tesaro, The Fly notes.
NVO Novo Nordisk
$49.46

0.805 (1.65%)

06/01/18
ROTH
06/01/18
NO CHANGE
Target $400
ROTH
Buy
Roth Capital ups Madrigal price target to $400, examines possible M&A scenarios
Roth Capital analyst Yasmeen Rahimi noted that Madrigal Pharmaceuticals' (MDGL) "impressive" NASH resolution results published yesterday resulted in the stock's value being pushed up to make it the highest among "purely NASH" companies. Among large pharma companies, Rahimi believes those with the strongest metabolic franchises, large R&D teams, and sales forces focused on endocrinologists, gastroenterologists, and hepatologists likely have eyes on NASH assets, listing Merck (MRK), AstraZeneca (AZN), Eli Lilly (LLY) and Novo Nordisk (NVO) as examples. The historical acquisition price for NASH assets ranges from $200M to $1.7B, but Rahimi argues that Madrigal "can set the highest NASH price tag yet," estimating a potential takeout valuation of $5.6B. Rahimi raised her price target on Madrigal shares to $400 from $210 and keeps a Buy rating on the stock.
07/02/18
BERN
07/02/18
UPGRADE
BERN
Outperform
Novo Nordisk upgraded to Outperform from Market Perform at Bernstein
04/05/18
RHCO
04/05/18
NO CHANGE
Target $101
RHCO
Buy
Eli Lilly supported by positive oncology and diabetes findings, says SunTrust
SunTrust analyst John Boris keeps his Buy rating and $101 price target on Eli Lilly (LLY), citing the latest developments in Oncology and Diabetes. In Oncology, Boris points to the positive Overall Survival and Progression Free Survival data for Cyramza in second-line hepatocellular carcinoma, though he sees the commercial opportunity in Hepatocellular Carcinoma as limited. In Diabetes, the analyst points to the latest data showing Trulicity gaining market share on Novo Nordisk's (NVO) Victoza in the GLP-1 market.
02/26/18
JPMS
02/26/18
NO CHANGE
Target $105
JPMS
Overweight
Concerns over Eli Lilly diabetes franchise overdone, says JPMorgan
JPMorgan analyst Chris Schott believes longer-term growth concerns surrounding Trulicity and Eli Lilly's (LLY) broader diabetes franchise are overdone following Novo Nordisk's (NVO) oral semaglutide results as well as the launch of Ozempic. The analyst sees a buying opportunity in shares of Eli Lilly following the recent pullback. Lilly is a "highly diversified growth story" and competition to Trulicity is manageable, Schott tells investors in a research note. He keeps an Overweight rating on the shares with a $105 price target.
NVS Novartis
$77.34

-0.12 (-0.15%)

07/02/18
HCWC
07/02/18
NO CHANGE
Target $10
HCWC
Buy
Adamis price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert raised his price target for Adamis Pharmaceuticals (ADMP) to $10 after the company announced that Novartis (NVS) division Sandoz division will commercialize Symjepi. While the deal took longer than expected, the terms of a 50:50 split is better than anticipated, Kolbert tells investors in a research note. The analyst sees Sandoz as a "great partner" and reiterates a Buy rating on Adamis.
06/29/18
ROTH
06/29/18
NO CHANGE
Target $22
ROTH
Buy
Cryoport price target raised to $22 from $12.50 at Roth Capital
Roth Capital analyst Richard Baldry reiterated a Buy rating on Cryoport (CYRX) and raised his price target to $22 from $12.50 after the EMA this morning recommended "marketing authorizations" for Gilead's (GILD) Yescarta and Novartis' (NVS) Kymriah, therapies developed by two of Cryoport's clients. In a research note to investors, Baldry said he believes the two approvals roughly double the addressable market for the therapies and offer upside potential to 2019 forecasts and sees further commercial approvals as likely.
07/02/18
RILY
07/02/18
NO CHANGE
Target $7.5
RILY
Buy
Adamis price target raised to $7.50 from $6.25 at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva raised his price target for Adamis Pharmaceuticals (ADMP) to $7.50 after the company entered into a strategic partnership with Novartis (NVS) unit Sandoz. The analyst views the agreement as favorable and keeps a Buy rating on Adamis.
07/02/18
ROTH
07/02/18
NO CHANGE
Target $22
ROTH
Buy
Cryoport price target raised to $22 from $12.50 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for Cryoport (CYRX) to $22 from $12.50 while reiterating a Buy rating on the shares. The analyst notes that the European Medicines Agency recommended "marketing authorizations" for therapies developed by two of Cryoport's clients, Gilead's (GILD) Yescarta and Novartis' (NVS) Kymriah. Baldry believes these two approvals roughly double the addressable market for the therapies and offer upside potential to our 2019 forecasts.
AZN AstraZeneca
$35.61

0.26 (0.74%)

05/31/18
SBSH
05/31/18
NO CHANGE
Target $100
SBSH
Buy
Amid investor questions, Citi reiterates $100 target on Tesaro
Citi analyst Robyn Karnauskas says she's been getting a lot of investor questions on Tesaro (TSRO) around the impact of Avastin approval on PARP use in first-line ovarian cancer, ahead of AstraZeneca's (AZN) Solo-1 data expected in the first half of 2018. After speaking to Tesaro's CEO, the analyst continues to be constructive on the quarter. The company believes that eventually Avastin will mostly be used in combinations, Karnauskas tells investors in a research note. She thinks Tesaro shares "will emerge" with crucial data expected in the latter half of the year. The analyst reiterates a Buy rating on the shares with a $100 price target.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
BMY Bristol-Myers
$56.26

-0.19 (-0.34%)

06/19/18
06/19/18
DOWNGRADE
Target $300

In Line
Madrigal cut to In Line at Evercore ISI following run-up in price, expectations
As previously reported, Evercore ISI analyst Josh Schimmer downgraded Madrigal Pharmaceuticals (MDGL) to In Line from Outperform, stating that he has no real incremental reason to raise his $300 price target, which the stock has achieved following the company's encouraging Phase 2 results for MGL-3196 and a Bloomberg report that has driven takeover speculation. Given current investor sentiment, anything short of either an acquisition or a "massive" collaboration like Bristol-Myers' (BMY) with Nektar (NKTR) will fall short of expectations, Schimmer tells investors.
05/24/18
MZHO
05/24/18
NO CHANGE
Target $103
MZHO
Buy
Nektar is Bristol-Myers' best chance in immuno-oncology, says Mizuho
Nektar Therapeutics' (NKTR) NKTR-214 asset is the best shot Bristol-Myers Squibb (BMY) has to retain its footing in the competitive immuno-oncology space, Mizuho analyst Difei Yang tells investors in a research note. The analyst says that recent data in non-small cell lung cancer presented by Merck (MRK) on Keytruda saw the company jump ahead of Bristol's Opdivo in this key indication. Upcoming data of the Opdivo/NKTR-214 combo at ASCO on June 2 will be key on 100 patients across multiple indications, Yang contends. She believes Bristol stands at risk of losing significant market share in the growing immuno-oncology space. Ahead of the data, the analyst reiterates a Buy rating on Nektar with a $103 price target.
LLY Eli Lilly
$88.14

0.26 (0.30%)

06/15/18
PIPR
06/15/18
NO CHANGE
Target $85
PIPR
Overweight
Piper Jaffray sees better than expected U.S. launch for Olumiant
Piper Jaffray analyst Tyler Van Buren says he left a meeting with CEO of Eli Lilly (LLY) David Ricks with increased conviction in the U.S. launch of Olumiant. The analyst believes the launch will be better than investors currently anticipate and reiterates an Overweight rating on shares of Incyte (INCY) with an $85 price target. Van Buren expect payors to be "very receptive" to Olumiant pricing.
07/10/18
CANT
07/10/18
NO CHANGE
Target $100
CANT
Overweight
Cantor sees positive results from Eli Lilly's cardiovascular outcomes study
Cantor Fitzgerald analyst Louise Chen reaffirms her Overweight rating on Eli Lilly with a $100 price target after speaking with four physicians to discuss the company's cardiovascular outcomes study for Trulicity known as Rewind. Most of the physicians expect a positive outcome for Rewind, Chen tells investors in a research note. A favorable outcome could increase Trulicity prescriptions by 20%-30% or by "multiples of current sales," the analyst contends. As such, she believes that "significant upside remains in the drug, if the doctors are right." Chen expects top-line data by year-end 2018.
GSK GlaxoSmithKline
$41.43

0.42 (1.02%)

04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.
JNJ Johnson & Johnson
$127.29

1.18 (0.94%)

07/06/18
RBCM
07/06/18
NO CHANGE
Target $143
RBCM
Outperform
Johnson & Johnson price target lowered to $143 from $155 at RBC Capital
RBC Capital analyst Glenn Novarro lowered his price target on Johnson & Johnson to $143 ahead of its Q2 results, saying the trends in the U.S. prescription drug market suggest that any upside in the company's Pharmaceutical segment is unlikely. Novarro expects the management to affirm its FY18 guidance for operational growth and earnings, but warns that the revenue guidance may see a downgrade due to the recent USD strength. The analyst also lowered his FY18 revenue projections to $81.1B from $81.3B and FY19 forecast to $80.6B from $83.0B.
06/27/18
MAXM
06/27/18
INITIATION
Target $6
MAXM
Buy
VistaGen Therapeutics initiated with a Buy at Maxim
As reported earlier, Maxim analyst Caroline Palomeque initiated VistaGen Therapeutics (VTGN) with a Buy rating and a price target of $6 based on its lead drug candidate, AV-101, an oral antidepressant targeting modulation of the NMDA receptor which is an emerging new class of antidepressants. The analyst notes that while Johnson & Johnson (JNJ) and Allergan (AGN) have first mover advantage in the NMDA class, their respective intranasal and IV in-office administration differentiates AV-101 as an oral at-home alternative. Palomeque notes the company's is progressing with its clinical development, as AV-101 undergoes phase 2 studies in treatment resistant major depressive disorder and adjunctive therapy in frontline failed patients, with data expected in the second half of this year and first half of 2019 respectively.
06/27/18
06/27/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zimmer Biomet (ZBH) initiated with an Underperform at Bernstein. 2. Abeona Therapeutics (ABEO) initiated with a Buy at B. Riley FBR. 3. Johnson & Johnson (JNJ) initiated with a Market Perform at Bernstein. 4. T-Mobile (TMUS) initiated with an Overweight at Barclays. 5. Scynexis (SCYX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$62.41

0.38 (0.61%)

06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
PFE Pfizer
$37.50

0.325 (0.87%)

06/08/18
06/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pfizer (PFE) and Eli Lilly (LLY) were initiated with an Overweight at Cantor Fitzgerald. 2. LivaNova (LIVN) initiated with a Buy at Stifel. 3. Occidental Petroleum (OXY) and Chevron (CVX) were initiated with a Buy at Mizuho while ConocoPhillips (COP) and Exxon Mobil (XOM) were initiated with a Neutral. 4. LeMaitre (LMAT) resumed with a Buy at Roth Capital. 5. Savara (SVRA) initiated with an Outperform, sees 300% upside, says Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/18
MSCO
06/19/18
NO CHANGE
Target $43
MSCO
Overweight
Pfizer doesn't appear focused on large-scale M&A, says Morgan Stanley
After meeting with Pfizer's head of IR, Chuck Triano, Morgan Stanley analyst David Risinger said his key takeaway was that the company sees the potential for "mid single digit plus" sales growth starting early next decade. Given that Lyrica is the only major patent expiration Pfizer will face over the next several years and that it has upcoming organic growth drivers, management seems focused on bolt-on acquisitions in existing therapeutic areas and large-scale M&A does not appear to be a focus, Risinger added. He keeps an Overweight rating and $43 price target on Pfizer shares.
SNY Sanofi
$42.13

0.29 (0.69%)

07/10/18
07/10/18
DOWNGRADE
Target $1

Neutral
Regulus downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst Liana Moussato downgraded Regulus (RGLS) to Neutral from Outperform after he extended developmental timelines due to partnership restructuring with Sanofi (SNY) pausing clinical enrollment for RG-012 and unexpected mouse toxicity observations delaying clinical progress for RGLS4326. The analyst also lowered his price target on Regulus shares to $1 from $3.
07/02/18
PIPR
07/02/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron has 'substantial' opportunity for Q2 upside, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that with Dupixent script trends indicated up almost 30% quarter-over-quarter, Regeneron's (REGN) opportunity for Q2 upside is "substantial." Further, Regeneron and Sanofi (SNY) over the weekend raised the list price by 3% for the drug's first ever price increase, Raymond tells investors in a research note. He thinks Dupixent remains well positioned to outperform expectations "this quarter and beyond." The analyst maintains an Overweight rating on Regeneron with a $450 price target.

TODAY'S FREE FLY STORIES

PSTG

Pure Storage

$23.40

1.1 (4.93%)

, NTAP

NetApp

$77.98

2.63 (3.49%)

05:10
10/17/18
10/17
05:10
10/17/18
05:10
Upgrade
Pure Storage, NetApp rating change  »

Pure Storage upgraded to…

PSTG

Pure Storage

$23.40

1.1 (4.93%)

NTAP

NetApp

$77.98

2.63 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

NTAP

NetApp

$77.98

2.63 (3.49%)

05:08
10/17/18
10/17
05:08
10/17/18
05:08
Upgrade
NetApp rating change  »

NetApp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

UAL

United Continental

$83.51

2.17 (2.67%)

05:04
10/17/18
10/17
05:04
10/17/18
05:04
Upgrade
United Continental rating change  »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ANZFF

Air New Zealand

$0.00

(0.00%)

05:01
10/17/18
10/17
05:01
10/17/18
05:01
Upgrade
Air New Zealand rating change  »

Air New Zealand upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$53.11

1.27 (2.45%)

04:59
10/17/18
10/17
04:59
10/17/18
04:59
Upgrade
Delta Air Lines rating change  »

Delta Air Lines upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AAL

American Airlines

$33.30

1.52 (4.78%)

04:58
10/17/18
10/17
04:58
10/17/18
04:58
Upgrade
American Airlines rating change  »

American Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

INFY

Infosys

$10.22

0.32 (3.23%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Downgrade
Infosys rating change  »

Infosys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

04:55
10/17/18
10/17
04:55
10/17/18
04:55
General news
Breaking General news story  »

Week of 10/12 MBA…

CYTK

Cytokinetics

$8.68

1.06 (13.91%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Cytokinetics management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 27

    Nov

LGND

Ligand

$210.86

10.8 (5.40%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Ligand management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 06

    Nov

LTS

Ladenburg Thalmann

$2.89

0.24 (9.06%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Ladenburg Thalmann management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Cowen healthcare analysts to hold an analyst/industry conference call »

Healthcare Analysts,…

NSSC

NAPCO Security

$14.13

0.51 (3.74%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
NAPCO Security management to meet with Benchmark »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 29

    Nov

SPLP

Steel Partners

$16.74

(0.00%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Steel Partners management to meet with Roth Capital »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SAIC

SAIC

$74.26

2.09 (2.90%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
SAIC management to meet with SunTrust »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AGLE

Aeglea BioTherapeutics

$10.04

0.6 (6.36%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Aeglea BioTherapeutics to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AGTC

Applied Genetic

$6.78

0.04 (0.59%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Applied Genetic management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

TRN

Trinity Industries

$37.12

0.4 (1.09%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Trinity Industries management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

OKTA

Okta

$61.89

3.66 (6.29%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Okta management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Stephens restaurants analyst to hold a luncheon meeting »

Restaurants Analyst…

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
RBC Capital IT services & payments analyst to hold luncheon meeting »

IT Services &…

04:55
10/17/18
10/17
04:55
10/17/18
04:55
General news
Housing Starts to be reported at 08:30 »

September Housing Starts…

OXM

Oxford Industries

$82.96

2.54 (3.16%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Oxford Industries management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

GNTX

Gentex

$19.36

0.13 (0.68%)

, HRS

Harris

$173.51

0.18 (0.10%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
National Business Aviation Association to hold a convention »

NBAA Business Aviation…

GNTX

Gentex

$19.36

0.13 (0.68%)

HRS

Harris

$173.51

0.18 (0.10%)

HON

Honeywell

$159.48

3.28 (2.10%)

LLL

L3 Technologies

$221.22

0.21 (0.10%)

PSX

Phillips 66

$109.84

2.63 (2.45%)

BAESY

BAE Systems

$0.00

(0.00%)

BA

Boeing

$368.10

9.29 (2.59%)

CAE

CAE

$19.12

0.175 (0.92%)

ERJ

Embraer

$20.25

0.77 (3.95%)

ESL

Esterline

$117.00

0.41 (0.35%)

GRMN

Garmin

$63.08

0.89 (1.43%)

NOC

Northrop Grumman

$312.12

6.51 (2.13%)

COL

Rockwell Collins

$135.11

0.37 (0.27%)

RYCEY

Rolls-Royce

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 24

    Oct

  • 24

    Oct

  • 26

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

EXPR

Express

$8.76

0.16 (1.86%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55
Conference/Events
Express management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.